Skip Navigation



PEDS Advance Access published online on June 23, 2009

Protein Engineering Design and Selection, doi:10.1093/protein/gzp025
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
22/8/479    most recent
gzp025v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Liu, L.
Right arrow Articles by Murphy, R. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, L.
Right arrow Articles by Murphy, R. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Differential modification of Cys10 alters transthyretin's effect on beta-amyloid aggregation and toxicity

Lin Liu1,5, Jie Hou1,6, Jiali Du1, Robert S. Chumanov2, Qingge Xu3, Ying Ge3, Jeffrey A. Johnson2,4 and Regina M. Murphy1,7

1Department of Chemical and Biological Engineering, University of Wisconsin, 1415 Engineering Drive, Madison, WI 53706 2Cellular and Molecular Biology Program and McArdle Laboratory for Cancer Research, University of Wisconsin, 1400 University Ave., Madison, WI 53706 3Human Proteomics Program, School of Medicine and Public Health, University of Wisconsin, 1300 University Ave., Madison, WI 53706 4Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin, 777 Highland Ave., Madison, WI 53705, USA 5Present address: Wyeth Pharmaceutical, 100 Academy St., Rouses Point, NY 12979, USA 6Present address: Shire PLC, 700 Main St., Cambridge, MA 02139, USA

7 To whom correspondence should be addressed. E-mail: regina{at}engr.wisc.edu

Tg2576 mice produce high levels of beta-amyloid (Aβ) and develop amyloid deposits, but lack neurofibrillary tangles and do not suffer the extensive neuronal cell loss characteristic of Alzheimer's disease. Protection from Aβ toxicity has been attributed to up-regulation of transthyretin (TTR), a normal component of plasma and cerebrospinal fluid. We compared the effect of TTR purified from human plasma (pTTR) with that produced recombinantly (rTTR) on Aβ aggregation and toxicity. pTTR slowed Aβ aggregation but failed to protect primary cortical neurons from Aβ toxicity. In contrast, rTTR accelerated aggregation, while effectively protecting neurons. This inverse correlation between Aβ aggregation kinetics and toxicity is consistent with the hypothesis that soluble intermediates rather than insoluble fibrils are the most toxic Aβ species. We carried out a detailed comparison of pTTR with rTTR to ascertain the probable cause of these different effects. No differences in secondary, tertiary or quaternary structure were detected. However, pTTR differed from rTTR in the extent and nature of modification at Cys10. We hypothesize that differential modification at Cys10 regulates TTR's effect on Aβ aggregation and toxicity.

Keywords: Alzheimer's disease/beta-amyloid/post-translational modification/transthyretin

Received May 20, 2009; revised May 20, 2009; accepted May 23, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.